Here we present a novel glucometer-based microfluidic platform using miniaturized personal glucose meter (PGM) with portability and simple operation to sensitively detect cancer biomarker via amplification of rolling cycle amplification (RCA) associated with DNA-invertase catalysis. This design utilizes gold nanoparticles (Au NPs) as a supporting matrix to anchor Human Epidermal Growth Factor Receptor 2 antibody (anti-HER2) and DNA sequence that is able to induce RCA. After adding HER2, a sandwiches immunocomplex forms between a peptide and the asymmetric DNA-anti-HER2-modified Au NPs in the detection area of a glass slide, followed by RCA process and hybridization of the RCA products with DNA-invertase for enzymatic generation of glucose. In such a way, RCA-amplified DNA converted glucose can be detected by PGM for sensitively diagnosis of HER2 biomarker. This assay is performed on a 43 × 43 mm microfluidic chip with small reagent volume, large dynamic range and high sensitivity, holding great promise in the clinical diagnosis at home or in urban area.

在这里，我们介绍了一种新型的基于葡萄糖计的微流控平台，该平台使用便携式个人血糖仪（PGM）具有便携性和简单的操作，可以通过与DNA转化酶催化相关的滚动循环扩增（RCA）的扩增来灵敏地检测癌症生物标志物。该设计利用金纳米颗粒（Au NPs）作为支持基质，锚定人类表皮生长因子受体2抗体（anti-HER2）和能够诱导RCA的DNA序列。加入HER2后，在载玻片的检测区域中，在肽和不对称的DNA-抗-HER2修饰的Au NP之间形成夹心免疫复合物，然后进行RCA处理，并将RCA产物与DNA转化酶杂交以酶促生成葡萄糖。以这样的方式，可以通过PGM检测RCA扩增的DNA转化的葡萄糖，以灵敏地诊断HER2生物标志物。该测定法在试剂体积小，动态范围大，灵敏度高的43×43 mm微流控芯片上进行，在家庭或城市地区的临床诊断中具有广阔的前景。